HRP20160863T1 - Supstituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za liječenje infekcija hepatitis c virusa - Google Patents
Supstituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za liječenje infekcija hepatitis c virusa Download PDFInfo
- Publication number
- HRP20160863T1 HRP20160863T1 HRP20160863TT HRP20160863T HRP20160863T1 HR P20160863 T1 HRP20160863 T1 HR P20160863T1 HR P20160863T T HRP20160863T T HR P20160863TT HR P20160863 T HRP20160863 T HR P20160863T HR P20160863 T1 HRP20160863 T1 HR P20160863T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- independently selected
- compound
- alkyl
- optionally substituted
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- -1 C1-C4 alkenyl ester Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- NAPDOWNULRULLI-UHFFFAOYSA-N 2-benzyl-1h-imidazole Chemical group C=1C=CC=CC=1CC1=NC=CN1 NAPDOWNULRULLI-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 239000005977 Ethylene Chemical group 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000256856 Vespidae Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (17)
1. Spoj prema formuli
T-R-J1-W-A-W-J1-R-T;T-R-J1-A-J1-R-T;T-R-J2-A-J2-R-T; T-R-J1-W-A-J1-R-T; T-R-J1-W-A-J2-R-T; ili T-R-J1-A-J2-R-T (Formula I)
ili njegova farmaceutski prihvatljiva sol,
gdje je
T neovisno izabran pri svakoj pojavi iz T1 i T2; i
T1 je -Y-Z, gdje je Y kovalentno vezano na R i Y je veza, C1-C4 alkilena opcionalno supstituirana s okso; i Z je 5 ili 6-člana heterociklična grupa, od kojih je svako T1 supstituiran s (i) najmanje jednim supstituentom izabranim iz -(C=O)OH, -(C=O)NH2, -(C=O)H, - C1-C4alkoksi, C2-C4 alkanoil, C1-C4alkilestar, C1-C4 alkenilestar, mono- ili di- C1-C4alkilkarboksamid i (ii) opcionalno supstituiran jednim ili više supstituenata neovisno izabranih iz halogena, hidroksila, C1-C2 alkila, i C1-C2 alkoksija;
T2 je neovisno izabran pri svakoj pojavi iz C2-C6 alkanoil, C1-C6alkilestar, C1-C6 alkenilestar, C1-C6alkilsulfonamid, C1-C6 alkilsulfonil, C2-C6alkanoil supstituiran s mono ili di- C1-C6 hidrokarbilkarbamata, C2-C6 alkanoil supstituiran s ureom ili mono- ili di- C1-C6 alkilureom, i C2-C6 alkanoil supstituiran s mono ili di- C1-C6alkilkarboksamidom, od kojih je svako T2 opcionalno supstituiran s 1 ili više supstituenata neovisno izabranih iz amino,cijano, hidroksil, halogen, (C1-C4 alkoksi) C0-C4 alkil, (mono- i di- C1-C4 alkilamino) C0-C4 alkil, C1-C6 alkil, (C1-C4tioalkil) C0-C4 alkil, C3-C7 cikloalkil, fenil, C1-C2 haloalkil, i C1-C2 haloalkoksi;
R je neovisno izabran na svakoj pojavi od 4- do 6-članih prstenova koji sadrže jedan ili dva atoma dušika s preostalim atomima prstena koji su ugljik, koji R je zasićen ili sadrži 1 nezasićenu vezu i opcionalno je spojen s metilen ili etilen mostom, ili je spojen na fenil ili 5- do 6-člani heteroarilni prsten; i
6- do 10-člani spojeni ili spiro biciklični sustav prstena koji sadrže jedan ili dva atoma dušika s preostalim atomima prstena koji su ugljik, čiji je 6- do 10-člani biciklični prsten zasićen ili sadrži 1 nezasićenu vezu; svaki R je opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz cijano, hidroksil, halogen, C1-C2 alkil, C1-C2 alkoksi, C1-C2 haloalkil, C1-C2 haloalkil, C1-C2haloalkilen, i C1-C2 alkilsulfonil;
J1 je fenil ili 5- do 6-člana heteroaril grupa koja sadrži 1 do 3 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je svaki J1 opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4alkil, C1-C4alkoksi, mono- i di- C1-C4alkilamino, C1-C2haloalkil, i C1-C2haloalkoksi;
J2 je 8- do 10-člana heteroaril grupa koja sadrži 1 do 4 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je J2 opcionalno susptituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4 alkil, C1-C4 alkoksi, mono-i di- C1-C4 alkilamino, C1-C2 haloalkil, i C1-C2haloalkoksi;
W se neovisno bira na svakoj pojavi i jest fenil, piridil ili alkinil grupa, opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4 alkil, C1-C4 alkoksi, mono-i di- C1-C4 alkilamino, C1-C2 haloalkil, i C1-C2 haloalkoksi; i
A je [j.k]-ciklofan, [j.k]-hetera-fan, [j.k]-hetero-fan, [j.k]-hetero-hetera-fan, ili [j.k]-alifan; gde j je cijeli broj od 1 do 4, k je cijeli broj od 1 do 4, razlika između j i k nije veća od 2, i svaki j i k linker opcionalno sadrži heteroatom izabran iz N, O, i S opcionalno supstituiranim s 1 okso grupom, i jednim ili više supstituenata neovisno izabranih iz halogena, hidroksija, amino, C1-C2alkil, i C1-C2 alkoksi; ili
A je [j.k.j’.k’]-ciklofan, gdje su j, j’, k, i k’ cijeli brojevi od 1 do 4, razlika između j i k ili k’ nije veća od 2, razlika između j’ i k ili k’ nije veća od 2, i svaki j, j’, k, i k’ linker opcionalno sadrži heteroatom izabran iz N, O, i S, i opcionalno je supstituiran s 1 okso grupom, i jednim ili više supstituenata neovisno izabranih iz halogen, hidroksi, amino, C1-C2 alkil, i C1-C2 alkoksi; ili
A je grupa prema formuli
[image]
pri čemu je Q neutralan ili kationski metal, svaki od od njih A je opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz halogen, hidroksi, C1-C2 alkil, i C1-C2 alkoksi; ili
A je grupa prema formuli
[image]
čije A je opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz halogena, C1-C2 alkil, i C1-C2 alkoksi.
2. Spoj ili sol prema patentnom zahtjevu 1, pri čemu A je jedan od
[image]
3. Spoj ili sol prema patentnom zahtjevu 1, pri čemu W je fenil, opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz halogena, C1-C2 alkil, i C1-C2 alkoksi.
4. Spoj ili sol prema patentnom zahtjevu 1, pri čemu J1 je
[image]
5. Spoj ili sol prema patentnom zahtjevu 1, pri čemu J2 je benzilimidazol grupa, opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz grupe halogena, C1-C2 alkil, i C1-C2 alkoksi.
6. Spoj ili sol prema patentnom zahtjevu 1, pri čemu je svaki R neovisno izabran iz
[image]
od kojih je svaki opcionalno supstituiran s jednim ili više supstituenata neovisno izabranih iz halogena, C1-C4 alkil, i C1-C4 alkoksi.
7. Spoj ili sol prema patentnom zahtjevu 6, pri čemu svaki R je neovisno izabran iz
[image]
8. Spoj ili sol prema patentnom zahtjevu 1 pri čemu je T neovisno izabrano C2-C6 alkanoil supstituiran s mono- i di- C1-C6 alkilkarbamatom, svaki od njihovih T je opcionalno supstituiran s (C1-C4 tioalkil) C0-C4 alkilom.
9. Spoj ili sol prema patentnom zahtjevu 1 prema formuli:
T-R-J2-A-J2-R-T;
gdje
A je grupa prema formuli
[image]
J2 je 8- do 10-člana heteroaril grupa koja sadrži 1 do 2 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je J2 opcionalno susptituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4 alkil, C1-C4 alkoksi, mono-i di- C1-C4 alkilamino, C1-C2 haloalkil, i C1-C2haloalkoksi;
Svako R je neovisno izabrano 8- do 10-članih bicikličnih sustava prstena koji sadrže jedan ili dva atoma dušika s preostalim atomima ugljika u prstenu, čiji 8- do 10-člani biciklični prsten je zasićen ili sadrži nezasićenu vezu;
svaki R je opcionalno susptituiran s jednim ili više supstituenata neovisno izabranih iz cijano, hidroksil, halogen, C1-C2 alkil, C1-C2 alkoksi, C1-C2 haloalkil, i C1-C2haloalkilen, i C1-C2 alkilsulfonil; i
T je T2.
10. Spoj ili sol prema patentnom zahtjevu 1, pri čemu se spoj izabire iz slijedeće grupe:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ose
[image]
11. Spoj ili sol prema patentnom zahtjevu 1 prema formuli:
[image]
12. Spoj ili sol prema patentnom zahtjevu 1 prema formuli:
[image]
13. Spoj ili sol prema patentnom zahtjevu 1 prema formuli:
[image]
14. Spoj ili sol prema patentnom zahtjevu 1 prema formuli:
[image]
15. Farmaceutski spoj koji obuhvaća spoj ili sol prema bilo kojem od prethodnih patentnih zahtjeva, zajedno s farmaceutski prihvatljivim nosačem.
16. Farmaceutski spoj prema patentnom zahtjevu 15, pri čemu spoj obuhvaća najmanje jedan dodatan aktivni agens.
17. Spoj ili sol prema bilo kojem od patentnih zahtjeva 1 do 14,ili farmaceutski spoj prema patentnom zahtjevu 15 ili patentnom zahtjevu 16, za uporabu u postupku liječenja infekcija hepatitisa C.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490881P | 2011-05-27 | 2011-05-27 | |
US201161504905P | 2011-07-06 | 2011-07-06 | |
US201161567216P | 2011-12-06 | 2011-12-06 | |
EP12793566.6A EP2714036B1 (en) | 2011-05-27 | 2012-05-29 | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
PCT/US2012/039835 WO2012166716A2 (en) | 2011-05-27 | 2012-05-29 | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160863T1 true HRP20160863T1 (hr) | 2016-11-04 |
Family
ID=47219638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160863TT HRP20160863T1 (hr) | 2011-05-27 | 2016-07-14 | Supstituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za liječenje infekcija hepatitis c virusa |
Country Status (25)
Country | Link |
---|---|
US (8) | US8809313B2 (hr) |
EP (2) | EP2714036B1 (hr) |
JP (2) | JP6198721B2 (hr) |
KR (1) | KR101931311B1 (hr) |
CN (2) | CN105801467A (hr) |
AP (1) | AP2013007263A0 (hr) |
AU (2) | AU2012262338B2 (hr) |
BR (1) | BR112013030045A2 (hr) |
CA (1) | CA2837481A1 (hr) |
CY (1) | CY1118111T1 (hr) |
EA (2) | EA201791776A1 (hr) |
ES (1) | ES2584418T3 (hr) |
HK (1) | HK1196559A1 (hr) |
HR (1) | HRP20160863T1 (hr) |
HU (1) | HUE029326T2 (hr) |
IL (3) | IL229165A (hr) |
LT (1) | LT2714036T (hr) |
MX (2) | MX349079B (hr) |
PL (1) | PL2714036T3 (hr) |
PT (1) | PT2714036T (hr) |
RS (1) | RS55123B1 (hr) |
SG (1) | SG194681A1 (hr) |
SI (1) | SI2714036T1 (hr) |
SM (1) | SMT201600325B (hr) |
WO (1) | WO2012166716A2 (hr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
EP2963034A1 (en) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Potent and selective inhibitors of hepatitis c virus |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SI2714036T1 (sl) | 2011-05-27 | 2016-10-28 | Achillion Pharmaceuticals, Inc. | Substituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani in metaloceni, uporabni pri zdravljenju okužb s HCV |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014169280A2 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
WO2015026454A1 (en) * | 2013-07-17 | 2015-02-26 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus |
EP3019196B1 (en) * | 2013-07-09 | 2018-06-06 | Bristol-Myers Squibb Company | Combinations of hepatitis c virus inhibitors |
WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
KR102538658B1 (ko) | 2014-08-04 | 2023-05-31 | 누에볼루션 에이/에스 | 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체 |
WO2016054240A1 (en) | 2014-09-30 | 2016-04-07 | Sean Dalziel | Fixed dose combinations for the treatment of viral diseases |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
CN108349907B (zh) * | 2015-11-06 | 2021-08-31 | 江苏豪森药业集团有限公司 | 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用 |
WO2017076194A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏豪森药业集团有限公司 | 具有抑制hcv活性的化合物及其制备方法和应用 |
CN106083829B (zh) * | 2016-01-12 | 2019-01-22 | 深圳市塔吉瑞生物医药有限公司 | 一种丙型肝炎病毒抑制剂、药物组合物及其应用 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2018064585A1 (en) * | 2016-09-29 | 2018-04-05 | Janssen Pharmaceuticals, Inc. | Odalasvir polymorphs and methods of manufacture thereof |
WO2018160892A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
KR20210057086A (ko) | 2018-09-06 | 2021-05-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | 다니코판의 형태체 형태 |
EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
AU2019346464A1 (en) | 2018-09-25 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
WO2020219808A1 (en) * | 2019-04-25 | 2020-10-29 | Beta Pharma, Inc. | Dicarbamate inhibitors of ns5a for treatment of hepatitis c virus infections and related diseases |
CA3160522A1 (en) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
WO2021198956A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN115181117B (zh) * | 2022-08-08 | 2024-05-17 | 中国医学科学院医学生物学研究所 | 一种s构型手性分子化合物及其制备方法和作为疫苗佐剂的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
DE4010531A1 (de) | 1990-04-02 | 1991-10-10 | Thomae Gmbh Dr K | Cyclophane, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JP3889708B2 (ja) * | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎トリペプチド阻害剤 |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EA200702445A1 (ru) | 2005-05-09 | 2008-04-28 | Ачиллион Фармасьютикалз, Инк. | Соединения тиазола и способы их применения |
EP2012799B1 (en) | 2006-05-03 | 2016-08-24 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
SI2041156T1 (sl) * | 2006-07-13 | 2014-04-30 | Achillion Pharmacetuticals, Inc. | Peptidi 4-amino-4-oksobutanoila kot inhibitorji virusne replikacije |
EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20100020484A (ko) | 2007-05-22 | 2010-02-22 | 아칠리온 파르마세우티칼스 인코포레이티드 | 헤테로아릴 치환된 티아졸 그리고 항-바이러스제로서의 그들의 사용 |
CA2700383A1 (en) * | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
NZ592110A (en) * | 2008-11-20 | 2012-06-29 | Achillion Pharmaceuticals Inc | Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
NZ592668A (en) * | 2008-12-10 | 2013-12-20 | Achillion Pharmaceuticals Inc | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
AU2009324644B2 (en) | 2008-12-10 | 2013-12-05 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
EP2393359A4 (en) * | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
EP2410844B1 (en) | 2009-03-27 | 2016-03-23 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
TWI476190B (zh) * | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
CN106588890B (zh) | 2009-05-13 | 2020-11-27 | 吉利德制药有限责任公司 | 抗病毒化合物 |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
WO2011050146A1 (en) * | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
EP2528926A4 (en) | 2010-01-28 | 2013-06-19 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
SI2714036T1 (sl) | 2011-05-27 | 2016-10-28 | Achillion Pharmaceuticals, Inc. | Substituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani in metaloceni, uporabni pri zdravljenju okužb s HCV |
-
2012
- 2012-05-29 SI SI201230643A patent/SI2714036T1/sl unknown
- 2012-05-29 PT PT127935666T patent/PT2714036T/pt unknown
- 2012-05-29 ES ES12793566.6T patent/ES2584418T3/es active Active
- 2012-05-29 EP EP12793566.6A patent/EP2714036B1/en active Active
- 2012-05-29 SG SG2013080155A patent/SG194681A1/en unknown
- 2012-05-29 CN CN201610206020.3A patent/CN105801467A/zh active Pending
- 2012-05-29 BR BR112013030045A patent/BR112013030045A2/pt not_active Application Discontinuation
- 2012-05-29 CN CN201280025427.6A patent/CN103561739B/zh not_active Expired - Fee Related
- 2012-05-29 AP AP2013007263A patent/AP2013007263A0/xx unknown
- 2012-05-29 US US13/482,558 patent/US8809313B2/en active Active
- 2012-05-29 LT LTEP12793566.6T patent/LT2714036T/lt unknown
- 2012-05-29 EA EA201791776A patent/EA201791776A1/ru unknown
- 2012-05-29 MX MX2013013670A patent/MX349079B/es active IP Right Grant
- 2012-05-29 HU HUE12793566A patent/HUE029326T2/hu unknown
- 2012-05-29 CA CA2837481A patent/CA2837481A1/en not_active Abandoned
- 2012-05-29 EP EP16157270.6A patent/EP3059241B1/en not_active Not-in-force
- 2012-05-29 MX MX2017001464A patent/MX357867B/es unknown
- 2012-05-29 EA EA201301335A patent/EA029099B1/ru not_active IP Right Cessation
- 2012-05-29 JP JP2014512183A patent/JP6198721B2/ja not_active Expired - Fee Related
- 2012-05-29 WO PCT/US2012/039835 patent/WO2012166716A2/en active Application Filing
- 2012-05-29 AU AU2012262338A patent/AU2012262338B2/en not_active Ceased
- 2012-05-29 RS RS20160570A patent/RS55123B1/sr unknown
- 2012-05-29 PL PL12793566T patent/PL2714036T3/pl unknown
- 2012-05-29 KR KR1020137031871A patent/KR101931311B1/ko active IP Right Grant
-
2013
- 2013-10-31 IL IL229165A patent/IL229165A/en active IP Right Grant
-
2014
- 2014-07-10 US US14/328,312 patent/US9273082B2/en not_active Expired - Fee Related
- 2014-10-09 HK HK14110090.2A patent/HK1196559A1/zh not_active IP Right Cessation
-
2015
- 2015-12-17 US US14/972,827 patent/US9468629B2/en not_active Expired - Fee Related
- 2015-12-17 US US14/972,913 patent/US9474742B2/en not_active Expired - Fee Related
-
2016
- 2016-07-14 HR HRP20160863TT patent/HRP20160863T1/hr unknown
- 2016-08-22 CY CY20161100824T patent/CY1118111T1/el unknown
- 2016-09-19 SM SM201600325T patent/SMT201600325B/it unknown
- 2016-09-20 US US15/271,066 patent/US9592222B2/en active Active
-
2017
- 2017-02-01 IL IL250389A patent/IL250389A/en not_active IP Right Cessation
- 2017-02-20 US US15/437,117 patent/US9833440B2/en active Active
- 2017-03-07 AU AU2017201535A patent/AU2017201535B2/en not_active Ceased
- 2017-03-09 JP JP2017044853A patent/JP2017101086A/ja active Pending
- 2017-09-11 IL IL254422A patent/IL254422A0/en unknown
- 2017-11-06 US US15/804,842 patent/US10092547B2/en active Active
-
2018
- 2018-06-29 US US16/024,021 patent/US20180303800A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160863T1 (hr) | Supstituirani alifani, ciklofani, heterafani, heterofani, hetero-heterafani i metaloceni korisni za liječenje infekcija hepatitis c virusa | |
MX2019011762A (es) | Compuesto de 4-piridona o su sal, y composicion y formulacion farmaceutica que incluye el mismo. | |
CA3045037A1 (en) | Compositions and methods for treating cdk4/6-mediated cancer | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
JP2014518882A5 (hr) | ||
CA2951911A1 (en) | Tank-binding kinase inhibitor compounds | |
AU2018247348A1 (en) | Amide compounds for the treatment of HIV | |
WO2009054332A1 (ja) | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
JP2015523383A5 (hr) | ||
TW200745061A (en) | Macrocylic inhibitors of hepatitis C virus | |
AR094312A1 (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
ES2623777T3 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
CN104507481A (zh) | 用于治疗、改善或预防病毒疾病的7-氧代-4,7-二氢-吡唑并[1,5-a]嘧啶衍生物 | |
CO6220931A2 (es) | Inhibidores de serina proteasas para el tratamiento de infecciones de vhc | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
WO2017133670A1 (en) | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza | |
CA2662196A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
CA2673254A1 (en) | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections | |
CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
WO2017133664A1 (en) | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza | |
AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
NZ571691A (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | |
PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos |